Omega Funds

Omega Funds

Omega Funds

Omega Funds global life sciences-based investment firm specialized in direct secondary transactions.
Follow us
Xconomy

Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma

Pulse 2.0

Kronos Bio Raises $155 Million In Private Financing

FinSMEs

Kronos Bio Raises $155M in Private Financing

€34,000,000 Venture capital (Series B)
FinSMEs

eTheRNA Raises €34M in Series B Financing

$85,000,000 Venture capital (Series C)
FinSMEs , Pulse 2.0

Checkmate Pharmaceuticals Raises $85M in Series C Financing

€10,000,000 Seed fund
FinSMEs

FoRx Therapeutics Closes €10M Seed Financing Round

$73,000,000 Venture capital (Series A)
Pulse 2.0

Biopharmaceutical Company Amunix Closes $73 Million In Funding

$88,000,000 Venture capital (Series B)
FinSMEs , Xconomy

Spruce Biosciences Raises $88M in Series B Financing

$180,000,000 IPO
MedCity News

Beam Therapeutics raises $180M in IPO

Xconomy

Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered

€20,000,000 Venture capital
FinSMEs

Anaconda Biomed Raises €20M Funding Round

Xconomy , MedCity News

Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug

MedCity News

Gene editing company Beam Therapeutics aims for $100M IPO

Xconomy

Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs

$40,000,000 Venture capital (Series B)
PE HUB , FinSMEs

Imago BioSciences raised $40 mln

$135,000,000 Venture capital (Series B)
FinSMEs

Beam Therapeutics Secures $135M in Series B Financing

PE HUB

VC-backed Gossamer Bio goes public

$276,000,000 IPO
Xconomy

Gossamer Bio Adds $276M in Second Biotech "Unicorn" IPO of 2019

MedCity News

Editas Medicine CEO steps down as company moves into product development stage

$22,000,000 Venture capital (Series C)
FinSMEs

Checkmate Pharmaceuticals Closes $22M Financing